Dysregulation of
cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations.
United States Patent 6,531,479 relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like.
By acting on different combinations of Cyclin Dependent Kinases it is possible to stop normal cells growing or to cause cancer cells to commit suicide, otherwise known as apoptosis.
The company is currently evaluating seliciclib (CYC202), an orally-available Cyclin Dependent Kinase inhibitor, in Phase II clinical trials for the treatment of non-small cell lung cancer and B-cell hematological malignancies.
Seliciclib is an orally available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets that are central to the process of cell division and cell cycle control.
The Company is currently evaluating seliciclib (CYC202), an orally available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer.
Seliciclib is an orally available
cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control.
Paracelsian's patented CDK assays measure the concentration of at least one
cyclin dependent kinase in the blood, plasma or serum of an animal or human, and correlates that concentration to the presence of abnormal cellular proliferation or tumor development in any tissue of the organism from which the sample was obtained.
